Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.
Haris Ali, MD, a hematology oncologist at the City of Hope Comprehensive Cancer Center, discusses the use of ruxolitinib (Jakafi) as peri-transplant treatment for patients with myelofibrosis.
According to Ali, the only approved treatment for myelofibrosis are the JAK inhibitors ruxolitinib and fedratinib (Inrebic). When patients progressed to the point where a transplant was needed, ruxolitinib was generally stopped. However, according to Ali, this abrupt stop was associated with ruxolitinib withdrawal syndrome.
Ruxolitinib withdrawal syndrome is a serious adverse event that manifests as circulatory shock. During ruxolitinib withdrawal syndrome, a patient can go into renal failure. According to Ali, the purpose of continuing ruxolitinib was not only to prevent withdrawal syndrome, but to also add to the beneficial effects of ruxolitinib during transplant. This may potentially decrease the risk of graft versus host disease and improve engraftment after transplant.
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More